CDMO Market Size 2026: The Data, the Market Leaders and the Outsourcing Opportunity
Updated: 8 hours ago
Updated 26 October 2026 with the 2025 revenue ranking of the 10 largest CDMOs, market share, and the BIOSECURE timeline. First published in June 2026.
The contract development and manufacturing organization (CDMO) sector is one of the most resilient growth stories in life sciences, and 2026 is shaping up to be a pivotal year. Pharma and biotech sponsors continue to externalize more of their development and manufacturing, specialist modalities keep multiplying, and demand for GLP-1 and biologics capacity is reshaping where the money flows. For CDMOs trying to win new programs, knowing the numbers is not academic: it tells you which segments are expanding fastest, where competition is thickest, and how to position a business development conversation.
This article pulls together current, sourced figures on the market, shows who the largest players are, breaks down the biologics versus small molecule story, and translates the data into practical implications for commercial teams.
Key Takeaways
Market scale: The global CDMO market is worth roughly USD 270 to 275 billion in 2026, depending on the research firm, with most forecasts pointing to USD 375 to 580 billion by the early 2030s.
Growth rate: Consensus growth sits in the 6 to 10 percent CAGR range, comfortably above broader pharma manufacturing, driven by rising outsourcing penetration.
A fragmented market: The 10 largest CDMOs reported about USD 35 billion of 2025 revenue combined, roughly 13 percent of the market, led by Lonza, Thermo Fisher Scientific and WuXi AppTec.
Biologics outpace small molecule: Biologics CDMO services are growing faster (roughly 7 to 15 percent CAGR depending on scope) than small molecule, though small molecule and APIs still hold the larger absolute share.
North America leads: North America remains the largest regional market, holding around 40 to 43 percent of small molecule CDMO revenue, with the US alone projected near USD 42 billion in 2026.
BD implication: Capacity in sterile fill/finish and specialized modalities is tight, so CDMOs that can credibly promise speed and capacity have real pricing and positioning leverage.
How big is the CDMO market in 2026?
Let's start with the headline number. CDMO market size estimates for 2026 vary by firm because each uses a different scope and methodology, but the cluster is tight enough to be useful. Mordor Intelligence puts the global pharmaceutical CDMO market at about USD 275.27 billion in 2026, growing to roughly USD 374.68 billion by 2031 at a 6.33 percent CAGR. Fortune Business Insights lands near USD 273.40 billion in 2026 but projects faster growth, around 9.90 percent CAGR, reaching about USD 580.72 billion by 2034.
More conservative scopes, such as Precedence Research, estimate about USD 211 billion in 2026 expanding to roughly USD 392.67 billion by 2035 at a 7.12 percent CAGR. The differences mostly come down to whether a firm counts only outsourced manufacturing or includes the full development-plus-manufacturing value chain.
The practical takeaway: treat any single figure as approximate. What matters is the direction and the pace. Every credible source agrees the market is growing meaningfully faster than the underlying pharmaceutical industry, because the share of work that sponsors outsource keeps rising.
CDMO market size 2026: a side-by-side comparison
The table below puts the leading 2026 estimates next to one another so you can see the range at a glance.
Source | 2026 market size (approx.) | Forecast | CAGR |
Mordor Intelligence | USD 275.27 billion | USD 374.68 billion by 2031 | ~6.33% |
Fortune Business Insights | USD 273.40 billion | USD 580.72 billion by 2034 | ~9.90% |
Precedence Research | USD 211 billion | USD 392.67 billion by 2035 | ~7.12% |
US market (Towards Healthcare) | USD 41.65 billion | USD 72.98 billion by 2035 | ~6.43% |
Reading across the rows, the spread on the 2026 figure (roughly USD 211 to 275 billion) is the scope effect described above. The spread on growth (6 to 10 percent) reflects different assumptions about how quickly biologics, GLP-1 and advanced modalities scale. For a business development plan, anchoring to the midpoint and qualifying it as "about" is the honest and defensible approach.
Who leads the CDMO market? The 10 largest CDMOs by 2025 revenue
GEN's Top 10 Contract Development and Manufacturing Organizations 2026, published on 10 September 2026, ranks CDMOs by 2025 revenue as disclosed in filings or reported to GEN. Figures are converted to US dollars, and some companies report only their CDMO or segment revenue.
Rank | Company | 2025 revenue (USD equivalent) |
1 | Lonza Group | about USD 8.05 billion (CHF 6.53 billion) |
2 | Thermo Fisher Scientific | USD 7.14 billion |
3 | WuXi AppTec | about USD 6.74 billion (RMB 45.45 billion) |
4 | WuXi Biologics | about USD 3.23 billion (RMB 21.79 billion) |
5 | Samsung Biologics | about USD 3.22 billion (KRW 4.56 trillion) |
6 | Boehringer Ingelheim | about USD 1.70 billion (EUR 1.47 billion) |
7 | Siegfried | about USD 1.64 billion (CHF 1.33 billion) |
8 | Fujifilm Biotechnologies | about USD 1.62 billion (JPY 257.2 billion) |
9 | Recipharm | about USD 0.97 billion (EUR 837 million) |
10 | AGC Biologics | about USD 0.81 billion (JPY 129.4 billion) |
Together, these ten companies reported about USD 35 billion of 2025 revenue, roughly 13 percent of a market estimated near USD 270 billion. The comparison is indicative rather than exact, because company revenue and market estimates use different scopes. But the message for BD teams is clear: the CDMO market remains fragmented, and most outsourcing spend goes to the long tail of mid-sized and specialist providers, not to the top ten.
Two of the top five, WuXi AppTec and WuXi Biologics, are headquartered in China, which is why the BIOSECURE debate matters so much to sponsors' sourcing plans. In the same GEN article, Corstrate's founder Imen Jelassi, PharmD, pointed to the ongoing reshoring of manufacturing by Western biopharma as a potential opportunity for US and European CDMOs, a theme we cover in our BIOSECURE Act analysis.
Biologics versus small molecule: where is growth concentrated?
The single most important segmentation question for a CDMO's commercial strategy is biologics versus small molecule, because the two have very different growth profiles, margins and capital requirements.
Biologics CDMO
Biologics is the faster-growing engine. Precedence Research calculates the biologics CDMO market at about USD 23.08 billion in 2025, rising to roughly USD 25.08 billion in 2026. MarketsandMarkets-style estimates put the 2026 figure near USD 27.13 billion, growing at about 7.14 percent CAGR to USD 38.29 billion by 2031. More aggressive scopes report CAGRs as high as 15.7 percent. The wide range again reflects scope, but the relative message is consistent: biologics is gaining share inside the CDMO mix.
Small molecule CDMO
Small molecule is the larger base and remains very much alive, contrary to the "biologics will eat everything" narrative. The small molecule innovator CDMO market is projected to climb from about USD 60.7 billion in 2025 to roughly USD 65.83 billion in 2026 at an 8.4 percent CAGR. The active pharmaceutical ingredient (API) CDMO segment is even bigger, projected at about USD 125.99 billion in 2026 on its way to roughly USD 247.60 billion by 2035 at a 7.81 percent CAGR, with the API segment holding around 38.5 percent of the overall market in 2025. High-potency APIs and peptide-based GLP-1 therapies are pulling small molecule growth upward, which is why writing off the segment would be a strategic mistake.
The honest summary: biologics grows faster in percentage terms, but small molecule plus API is the larger absolute market and is being revitalized by GLP-1 peptides and HPAPIs. A CDMO's positioning should reflect which of these it actually serves, not which sounds more exciting.
Regional picture: North America leads, Europe and Asia-Pacific scale
Geography still matters enormously for business development, because proximity, regulatory familiarity and supply chain security all influence sponsor decisions. North America held the dominant position in small molecule CDMO, accounting for about 42.7 percent share and roughly USD 29.1 billion in 2024, and around 40 percent of the global small molecule CMO and CDMO market. The US pharmaceutical CDMO market alone is forecast to rise from about USD 41.65 billion in 2026 to roughly USD 72.98 billion by 2035 at a 6.43 percent CAGR.
Asia-Pacific is the fastest-growing region in percentage terms, with specific country markets exhibiting CAGRs near 9.4 percent, partly on cost and partly on expanding domestic biotech. Europe sits between the two: a mature, quality-driven market where supply chain resilience and "friendly-shoring" of critical APIs are increasingly part of the sponsor conversation. For CDMOs targeting US and EU sponsors, the resilience-and-reshoring theme is now a credible differentiator, not just a talking point.
What is driving CDMO growth into 2026?
Several forces are compounding. First, GLP-1 demand: total GLP-1 sales are projected to exceed USD 200 billion annually by 2031, and the buildout to meet that demand accelerates in earnest in 2026, with sponsors like Eli Lilly investing in multi-billion-dollar facilities. Second, capacity constraints: sterile fill/finish capacity remains tight and specialized modalities have a backlog, which is expected to persist through 2026.
Third, biotech funding is back, but concentrated: HSBC Innovation Banking counts USD 16 billion of private biopharma investment across 314 deals in H1 2026, with the top 10 percent of first financings taking 63 percent of the money. Fourth, reshoring: the BIOSECURE Act became law on 18 December 2025, the first list of biotechnology companies of concern is expected around December 2026, and federal contracting prohibitions will follow once procurement rules are revised. Sponsors planning programs that run into 2028 and beyond are already factoring it into CDMO selection.
For business development, tight capacity is a double-edged sword. It gives CDMOs pricing leverage, but it also means sponsors are doing more diligence on whether a partner can actually deliver on time. The winning BD narrative in 2026 leads with demonstrable capacity and speed, backed by evidence, rather than a generic capabilities list.
Turning market data into a business development advantage
Numbers only matter if they change what you do on Monday morning. A CDMO that understands the 2026 market can prioritize the segments where demand outpaces supply (sterile fill/finish, peptides, biologics), tailor outreach to the regions where its quality and proximity story resonates, and qualify leads against the modalities it genuinely excels at. This is exactly the kind of market-informed targeting that separates a predictable pipeline from spray-and-pray outreach. For CDMO leadership teams that want to turn this data into a commercial plan, our fractional CCO and commercial advisory service covers segment prioritization and positioning.
If you need a senior BD lead to work these segments part time, see our fractional BD service for CDMOs.
If you want to translate these trends into a structured pipeline, our guide to pipeline optimization walks through building a predictable revenue engine, and our breakdown of business development challenges for CDMOs addresses the specific commercial hurdles this sector faces. For the upstream demand-generation side, pharmaceutical lead generation covers how to fill the top of the funnel, and if you are weighing channel strategy, inbound vs outbound in life sciences explains why you need both.
Frequently asked questions
How big is the CDMO market in 2026?
The global CDMO market is worth roughly USD 211 to 275 billion in 2026, depending on the research firm and the scope of services counted. Most estimates cluster around USD 270 billion, with forecasts reaching USD 375 to 580 billion by the early-to-mid 2030s.
What is the CDMO market growth rate?
Consensus growth sits in the 6 to 10 percent CAGR range. Mordor Intelligence cites about 6.33 percent to 2031, while Fortune Business Insights projects closer to 9.90 percent to 2034. Biologics and GLP-1-related capacity grow faster than the overall average.
Who are the largest CDMOs?
By 2025 revenue, GEN ranks Lonza first (about USD 8.1 billion), followed by Thermo Fisher Scientific (USD 7.1 billion), WuXi AppTec (USD 6.7 billion), WuXi Biologics and Samsung Biologics (about USD 3.2 billion each), then Boehringer Ingelheim, Siegfried, Fujifilm, Recipharm and AGC Biologics.
What share of the CDMO market do the top players hold?
The ten largest CDMOs in GEN's 2026 ranking reported about USD 35 billion of 2025 revenue combined, roughly 13 percent of a market estimated near USD 270 billion. The figure is indicative, because some companies report only segment revenue, but it shows how fragmented the CDMO market remains.
Is biologics or small molecule growing faster in the CDMO market?
Biologics is growing faster in percentage terms, with CAGRs reported between roughly 7 and 15 percent depending on scope. However, small molecule plus API services remain the larger absolute market and are being revitalized by GLP-1 peptides and high-potency APIs.
Which region has the largest CDMO market?
North America is the largest, holding around 40 to 43 percent of small molecule CDMO revenue, with the US market alone forecast near USD 42 billion in 2026. Asia-Pacific is the fastest-growing region, and Europe is a mature, quality-driven market increasingly shaped by supply chain resilience.
Why is the CDMO market growing so quickly?
Four drivers dominate: surging GLP-1 demand (projected above USD 200 billion in annual sales by 2031), persistent capacity constraints in sterile fill/finish and advanced modalities, a recovering biotech funding environment, and supply chain reshoring accelerated by the BIOSECURE Act.
Sources
Author: Imen Jelassi, PharmD, Founder and CEO, Corstrate, a business development consultancy for CDMOs, CROs and life sciences service providers.
Comments